"RIV/62156489:43210/10:00184900!RIV12-GA0-43210___" . "1802-4475" . "12" . . "5"^^ . . "[5566BAAF4562]" . "Nov\u00E9 mo\u017Enosti v laboratorn\u00ED diagnostice karcinomu prostaty" . . "9"^^ . "Nov\u00E9 mo\u017Enosti v laboratorn\u00ED diagnostice karcinomu prostaty" . . "prostate; maeker; cancer"@en . "N\u00E1dorov\u00E1 onemocn\u011Bn\u00ED prostaty pat\u0159\u00ED k nej\u010Dast\u011Bj\u0161\u00EDm n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm mu\u017E\u016F v Evrop\u011B i ve sv\u011Bt\u011B. D\u00EDky vysok\u00E9 incidenci tohoto onemocn\u011Bn\u00ED dosahuje tak\u00E9 \u00FAmrtnost alarmuj\u00EDc\u00EDch hodnot. Nicm\u00E9n\u011B, ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F jde o klinicky n\u011Bm\u00E9 formy, \u010Dasto prok\u00E1zan\u00E9 a\u017E p\u0159i pitv\u011B zem\u0159el\u00FDch na jinou p\u0159\u00ED\u010Dinu. Stanoven\u00ED hladiny PSA nekoreluje s klinickou z\u00E1va\u017Enost\u00ED onemocn\u011Bn\u00ED a inklinuje k %22p\u0159ediagnostikov\u00E1n\u00ED%22 pacient\u016F. D\u016Fsledkem tohoto je zejm\u00E9na v\u00FDznamn\u00E1 - zbyte\u010Dn\u00E1 - psychick\u00E1 z\u00E1t\u011B\u017E pacient\u016F a ne nev\u00FDznamn\u00E9 ekonomick\u00E9 d\u016Fsledky spojen\u00E9 s dal\u0161\u00EDmi diagnostick\u00FDmi procedurami. C\u00EDlem pr\u00E1ce je nal\u00E9zt nov\u00E9 markery tohoto onemocn\u011Bn\u00ED. Sarcosin je p\u0159\u00EDrodn\u00ED ve vod\u011B rozpustn\u00E1 aminokyselina, kter\u00E1 nen\u00ED toxick\u00E1. I v p\u0159\u00EDpad\u011B ran\u00FDch stadi\u00ED v\u00FDvoje n\u00E1doru je sarcosin cenn\u00FDm vod\u00EDtkem. Nejm\u00E9n\u011B cenn\u00E9 je i to, \u017Ee ve vzorc\u00EDch mo\u010Di odebran\u00FDch zdrav\u00FDm pacient\u016Fm nebyl v\u016Fbec p\u0159\u00EDtomen. T\u00EDm se minimalizuje pravd\u011Bpodobnost fale\u0161n\u00E9 pozitivity. Podle zve\u0159ejn\u011Bn\u00FDch v\u00FDsledk\u016F je sarcosin podstatn\u011B lep\u0161\u00ED indik\u00E1tor postupuj\u00EDc\u00ED rakoviny ne\u017E PSA. P\u0159\u00EDtomnost aminokyseliny sarcosinu upozor\u0148uje pr\u00E1v\u011B na agresivn\u00ED n\u00E1dory. Pro tento \u00FA\u010Del je hled\u00E1na vhodn\u00E1 a jednoduch\u00E1 analytick\u00E1 metodika. D\u00E1le je n\u00E1dorov\u00E1 transformace karcinomu prostaty je spojena s dysregulac\u00ED metabolismu t\u011B\u017Ek\u00FDch kov\u016F. Doch\u00E1z\u00ED proto - dosud nezn\u00E1m\u00FDmi mechanismy - ke zv\u00FD\u0161en\u00ED s\u00E9rov\u00E9 hladiny metalothioneinu (MT), n\u00EDzkomolekul\u00E1rn\u00EDho na cystein bohat\u00E9ho proteinu s antioxida\u010Dn\u00EDm potenci\u00E1lem, \u00FA\u010Dastn\u00E9ho detoxikace t\u011B\u017Ek\u00FDch kov\u016F. Hladina MT je statisticky v\u00FDznamn\u011B zv\u00FD\u0161ena (p < 0,01) v s\u00E9ru pacient\u016F s biopticky ov\u011B\u0159en\u00FDm acin\u00E1rn\u00EDm adenokarcinomem (nej\u010Dast\u011Bj\u0161\u00ED formou Ca prostaty) o stagingu T 1c-4; oproti kontroln\u00EDmu souboru jsou hladiny zv\u00FD\u0161eny v\u00EDce ne\u017E trojn\u00E1sobn\u011B. Senzitivita zv\u00FD\u0161en\u00ED je v souboru pacient\u016F 100%. Hladina MT nen\u00ED z\u00E1visl\u00E1 (koeficient korelace r < 0,2, p\u0159\u00EDpadn\u011B vy\u0161\u0161\u00ED a statisticky nev\u00FDznamn\u00FD) na hladin\u011B PSA, na stagingu onemocn\u011Bn\u00ED a na p\u0159\u00EDtomnosti komorbidit hypertenzn\u00ED nemoci, hyperlipoprotein\u00E9mie a ischemick\u00E9 choroby srde\u010Dn\u00ED. Hladina MT se sni\u017Euje"@cs . . . . . . "Hrabec, Roman" . "N\u00E1dorov\u00E1 onemocn\u011Bn\u00ED prostaty pat\u0159\u00ED k nej\u010Dast\u011Bj\u0161\u00EDm n\u00E1dorov\u00FDm onemocn\u011Bn\u00EDm mu\u017E\u016F v Evrop\u011B i ve sv\u011Bt\u011B. D\u00EDky vysok\u00E9 incidenci tohoto onemocn\u011Bn\u00ED dosahuje tak\u00E9 \u00FAmrtnost alarmuj\u00EDc\u00EDch hodnot. Nicm\u00E9n\u011B, ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F jde o klinicky n\u011Bm\u00E9 formy, \u010Dasto prok\u00E1zan\u00E9 a\u017E p\u0159i pitv\u011B zem\u0159el\u00FDch na jinou p\u0159\u00ED\u010Dinu. Stanoven\u00ED hladiny PSA nekoreluje s klinickou z\u00E1va\u017Enost\u00ED onemocn\u011Bn\u00ED a inklinuje k %22p\u0159ediagnostikov\u00E1n\u00ED%22 pacient\u016F. D\u016Fsledkem tohoto je zejm\u00E9na v\u00FDznamn\u00E1 - zbyte\u010Dn\u00E1 - psychick\u00E1 z\u00E1t\u011B\u017E pacient\u016F a ne nev\u00FDznamn\u00E9 ekonomick\u00E9 d\u016Fsledky spojen\u00E9 s dal\u0161\u00EDmi diagnostick\u00FDmi procedurami. C\u00EDlem pr\u00E1ce je nal\u00E9zt nov\u00E9 markery tohoto onemocn\u011Bn\u00ED. Sarcosin je p\u0159\u00EDrodn\u00ED ve vod\u011B rozpustn\u00E1 aminokyselina, kter\u00E1 nen\u00ED toxick\u00E1. I v p\u0159\u00EDpad\u011B ran\u00FDch stadi\u00ED v\u00FDvoje n\u00E1doru je sarcosin cenn\u00FDm vod\u00EDtkem. Nejm\u00E9n\u011B cenn\u00E9 je i to, \u017Ee ve vzorc\u00EDch mo\u010Di odebran\u00FDch zdrav\u00FDm pacient\u016Fm nebyl v\u016Fbec p\u0159\u00EDtomen. T\u00EDm se minimalizuje pravd\u011Bpodobnost fale\u0161n\u00E9 pozitivity. Podle zve\u0159ejn\u011Bn\u00FDch v\u00FDsledk\u016F je sarcosin podstatn\u011B lep\u0161\u00ED indik\u00E1tor postupuj\u00EDc\u00ED rakoviny ne\u017E PSA. P\u0159\u00EDtomnost aminokyseliny sarcosinu upozor\u0148uje pr\u00E1v\u011B na agresivn\u00ED n\u00E1dory. Pro tento \u00FA\u010Del je hled\u00E1na vhodn\u00E1 a jednoduch\u00E1 analytick\u00E1 metodika. D\u00E1le je n\u00E1dorov\u00E1 transformace karcinomu prostaty je spojena s dysregulac\u00ED metabolismu t\u011B\u017Ek\u00FDch kov\u016F. Doch\u00E1z\u00ED proto - dosud nezn\u00E1m\u00FDmi mechanismy - ke zv\u00FD\u0161en\u00ED s\u00E9rov\u00E9 hladiny metalothioneinu (MT), n\u00EDzkomolekul\u00E1rn\u00EDho na cystein bohat\u00E9ho proteinu s antioxida\u010Dn\u00EDm potenci\u00E1lem, \u00FA\u010Dastn\u00E9ho detoxikace t\u011B\u017Ek\u00FDch kov\u016F. Hladina MT je statisticky v\u00FDznamn\u011B zv\u00FD\u0161ena (p < 0,01) v s\u00E9ru pacient\u016F s biopticky ov\u011B\u0159en\u00FDm acin\u00E1rn\u00EDm adenokarcinomem (nej\u010Dast\u011Bj\u0161\u00ED formou Ca prostaty) o stagingu T 1c-4; oproti kontroln\u00EDmu souboru jsou hladiny zv\u00FD\u0161eny v\u00EDce ne\u017E trojn\u00E1sobn\u011B. Senzitivita zv\u00FD\u0161en\u00ED je v souboru pacient\u016F 100%. Hladina MT nen\u00ED z\u00E1visl\u00E1 (koeficient korelace r < 0,2, p\u0159\u00EDpadn\u011B vy\u0161\u0161\u00ED a statisticky nev\u00FDznamn\u00FD) na hladin\u011B PSA, na stagingu onemocn\u011Bn\u00ED a na p\u0159\u00EDtomnosti komorbidit hypertenzn\u00ED nemoci, hyperlipoprotein\u00E9mie a ischemick\u00E9 choroby srde\u010Dn\u00ED. Hladina MT se sni\u017Euje" . . "4" . "Masa\u0159\u00EDk, Michal" . "Cernei, Natalia Vladimirovna" . "2"^^ . . . "K\u0159\u00ED\u017Ekov\u00E1, So\u0148a" . "275300" . "Prostate Cancer is one of the most common cancer of men in Europe and worldwide. Due to the high incidence of this disease mortality also reached alarming values. However, in most cases it is clinically silent forms, often demonstrated only at autopsy who died of other causes. Determination of PSA levels correlate with clinical severity of the disease and tends to %22p\u0159ediagnostikov\u00E1n\u00ED%22 patients. The consequence of this is particularly important - unnecessary - mental stress of patients and no significant economic implications associated with other diagnostic procedures. The goal is to find new markers of disease. Sarcosin is a natural water-soluble amino acid which is toxic. Even if the early stages of tumor development is a valuable sarcosin. The least valuable is the fact that in urine samples taken from healthy patients was not present. This minimizes the chance of false positives. According to published results sarcosin much better indicator of advancing cancer than PSA. The presence of amino acids sarcosinu attention just on aggressive tumors. For this purpose, searching for a suitable and simple analytical methodology. Furthermore, the transformation of prostate cancer is associated with metabolic dysregulation of heavy metals. There is so - yet unknown mechanism - to raise serum levels of metallothionein (MT), low molecular weight cysteine-rich protein with antioxidant potential, compassionately detoxification of heavy metals. MT levels are significantly increased (p <0.01) in serum of patients with biopsy-proven acin\u00E1rn\u00EDm adenocarcinoma (the most common form of prostate Ca) on the staging of the T 1c-4, compared with the control group levels are increased more than threefold. Sensitivity increase is 100% of patients. MT levels are not dependent (correlation coefficient r <0.2 or higher and statistically insignificant) in the PSA for staging the disease and the presence of comorbidities hypertension, hyperlipoproteinemia and ischemic heart disease. MT l"@en . . . . "Babula, Petr" . "New possibilities in laboratory diagnosis of prostate cancer"@en . "Masa\u0159\u00EDkov\u00E1, M." . "Nov\u00E9 mo\u017Enosti v laboratorn\u00ED diagnostice karcinomu prostaty"@cs . "RIV/62156489:43210/10:00184900" . . "43210" . . "Kizek, Ren\u00E9" . "New possibilities in laboratory diagnosis of prostate cancer"@en . "Rovn\u00FD, Arne" . "Onkologie" . "Gumulec, Jarom\u00EDr" . . . "CZ - \u010Cesk\u00E1 republika" . "Nov\u00E9 mo\u017Enosti v laboratorn\u00ED diagnostice karcinomu prostaty"@cs . "P(GP301/09/P436)" .